The Queen Elizabeth Hospital

Nipocalimab Shows Promise in Phase II Trial for Sjögren's Syndrome

6 months ago

• Nipocalimab, an anti-IgG monoclonal antibody, demonstrated significant improvement in clinical ESSDAI scores in patients with primary Sjögren's syndrome. • A phase II trial revealed that patients receiving 15 mg/kg of nipocalimab every two weeks experienced a greater reduction in disease activity compared to placebo. • The higher dose of nipocalimab also led to improvements in Physician's Global Assessment and responder rates based on STAR and CRESS standards. • Janssen, the developer, is planning a phase III study to further evaluate the efficacy and safety of nipocalimab in treating Sjögren's syndrome.